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Asbestos, a known occupational pollutant, may upregulate the activity of inducible nitric oxide synthase (iNOS) and thus the
production of nitric oxide (NO). This study investigated whether iNOS(CCTTT)n polymorphism is associated with an increased
asbestosisriskinexposedworkers.Thestudycohortconsistedof262caseswithasbestosisand265controlswithnoasbestos-related
disease. For each subject the cumulative asbestos exposure data were available. The number of CCTTT repeats was determined
following PCR ampliﬁcation of the iNOS promoter region. Logistic regression was performed to estimate asbestosis risk. The OR
of asbestosis was 1.20 (95% CI = 0.85–1.69) for the LL genotype compared to the combined SL and SS genotypes and 1.26 (95%
CI = 0.86–1.85) for the LL genotype compared to the SL genotype. The results of this study are borderline signiﬁcant and suggest
a possible role of iNOS(CCTTT)n polymorphism in the risk of asbestosis; however, further studies are needed.
1.Introduction
Asbestosisisoneofthemost frequentlystudieddiseases asso-
ciated with the inhalation of asbestos ﬁbers. The exposure to
asbestos is known to cause inﬂammation, ﬁbrous scarring
in the lung, and cancer [1, 2]. It has been suggested that,
in addition to reactive oxygen species (ROS), the reactive
nitric species (RNS), such as nitric oxide (NO), may also be
involved in the development of asbestos-related diseases [3–
6].
Nitric oxide is a free radical which readily reacts with
ROS, such as superoxide anion, producing peroxynitrite,
which cangeneratehydroxyl radicals [7–11]. Inthe living or-
ganisms NO is synthesized by nitric oxide synthases (NOSs),
which catalyse the conversion of amino acid L-arginine and
molecular oxygen into NO and L-citrulline [11, 12]. Three
isoforms ofNOShave beenidentiﬁed: neuronal NOS(nNOS
or NOS1), inducible NOS (iNOS or NOS2), and endothelial
NOS(eNOSor NOS3)[7]. InducibleNOSis often present at
sites of chronic inﬂammation [5, 11].
Nitric oxide generation is thought to be an important
mediator of cell injury and inﬂammation caused by asbestos
[13]. Studies indicate that asbestos ﬁbers may upregulate
the activity of iNOS and thus the production of NO by
alveolar macrophages and pulmonary epithelial cells [5, 6,
13–15]. Several studies described the association between
NO production and the adverse eﬀects of asbestos [3–6, 13].
Chaoetal.reported anassociation betweenthemagnitudeof
NO production by lung epithelial cells and DNA oxidation
a ti nv i t r oe x p o s u r et oa s b e s t o s[ 3]. Treatment of human
lung epithelial cells with asbestos was shown to result in
the synthesis of iNOS mRNA and increased intracellular
levels of nitrate, a stable oxidation product of NO [3]. In
addition, a temporal correlation was demonstrated between
NO production by alveolar macrophages and neutrophil
inﬁltration into lung after inhalation of asbestos [13]. The
ﬁndings of these studies suggest that NO may play an
important role in the initiation and progression of asbestosis
[6]. However, the studies in iNOS knockout mice indicate
that iNOS-derived NO exerts a dual role in acute asbestos-
induced lung injury as iNOS deﬁciency resulted in an
exacerbated inﬂammatory response but improved oxidant-
promoted lung tissue damage [16].
The human iNOS gene is polymorphic. Several types of
polymorphisms have been identiﬁed in the promoter region
of the iNOS gene, among them the tandem repeat number2 Journal of Biomedicine and Biotechnology
polymorphism of a CCTTT pentanucleotide ((CCTTT)n)
[17, 18]. The CCTTT pentanucleotide repeats within the
promotor region of the human iNOS gene have been asso-
ciated with the biochemical promoter activity [19]. Several
studies have suggested an association between inﬂammatory
diseases or cancer and the number of the CCTTT repeats
[18–21]. However, to our knowledge and according to the
literature available, this polymorphism has not been studied
so far in association with asbestosis.
In this study we investigated whether iNOS (CCTTT)n
polymorphismisassociatedwithanincreasedrisk ofasbesto-
sis in workers exposed to asbestos.
2.Methods
The study population comprised 262 subjects who were
diagnosed with asbestosis as an occupational disease and
265 subjects with no asbestos disease as the control group.
Cases and controls were matched by gender and age. All
the subjects were selected from a cohort of 2080 workers
who were occupationally exposed to asbestos in the asbestos
cement manufacturing plant of Salonit Anhovo, Slovenia,
and presented at the State Board for Recognition of Occu-
pational Asbestos Diseases in the period between 1 January
1998 and 31 December 2003 [22].
To obtain the information about smoking, all cases and
controls were interviewed by the same investigator, using a
standardized questionnaire [23, 24]. Foreach subject includ-
ed in the present study, the cumulative asbestos exposure
data were obtained from the previous study [24].
The diagnosis of asbestosis or “no asbestos-related
disease” was conﬁrmed by two groups of experienced oc-
cupational experts of the State Board for Recognition of
Occupational Asbestos Diseases at the Clinical Institute of
Occupational Medicine. Each group of experts consisted of
an occupational physician, a radiologist, and a pulmonolo-
gist skilled in diagnosis of asbestos-related diseases. The
diagnosis was based on the Helsinki Criteria for Diagnosis
and Attribution of Asbestos Diseases [25]a n do nt h e
American Thoracic Society recommendations [26]. High-
Resolution Computer Tomography (HRCT) was used for
radiological diagnosis of asbestosis. In about 1% of subjects,
the histopathological examination was performed as well.
Genotypingofthe(CCTTT)n intheiNOS genepromoter
was performed by the ampliﬁcation of the corresponding
region of the promoter by PCR using a primer pair with
one primer being ﬂuorescently labelled [27]. The ampliﬁed
fragments were analysed on the ABI PRISM 310 Genetic
Analyser (Applied Biosystems), and the number of poly-
morphic repeats was determined with GeneMapper analysis
software (Applied Biosystems, Norwalk, USA) as previously
reported [28].
First, the statistical analysis included the descriptive
statistics, t-test, and χ2 test. Next, univariate logistic regres-
sion was performed to estimate the risk of asbestosis in
relation to individual variables (iNOS, cumulative asbestos
exposure, gender, age, and smoking). These analyses were
followed by multivariate logistic regression modelling.
Table 1: Allele frequencies of the iNOS (CCTTT)n gene polymor-
phism in cases and controls.
No. ofCCTTT repeats Size
(bp)
Cases
N (%)
Controls
N (%)
6 166 1 1
7 171 1 2
8 176 0 2
9 181 20 22
10 186 72 71
11 191 75 82
12 196 193 173
13 201 93 96
14 206 32 33
15 211 24 31
16 216 3 3
17 221 2 1
18 226 0 1
≤11 (short alleles) 169 180
≥12 (long alleles) 347 338
3.Results
The subjects with asbestosis were on average 61 and the
controls 57 years old (t = 5.18, P = .000). Comparison
of smoking between the cases and the controls showed no
statistically signiﬁcant diﬀerence (χ2 = 0.01, P = .919).
Approximately forty-ﬁve percent of subjects (117 cases and
120 controls) were ever smokers.
The average cumulative asbestos exposure was signiﬁ-
cantly higher in subjects with asbestosis compared to those
without asbestos-related disease (37.67 ﬁbres/cm3-years for
cases and 11.23 ﬁbres/cm3-years for controls; = 4.78, P =
.000).
Genotypingofthe(CCTTT)n intheiNOSgenepromoter
was successful in 258 cases and 259 controls. Thirteen alleles
for the iNOS microsatellite ranging from 166 to 226 base
pears (bp) (6 to 18 CCTTT repeats) were observed (Table 1).
The alleles with ≤11 CCTTT repeats were deﬁned as short
alleles (S) and alleles with ≥12 repeats as long alleles (L)
(Table 1).
Accordingly,thesubjectswereclassiﬁed intothreegroups
of genotypes: SS, SL, and LL. Inducible nitric oxide synthase
LL genotype was observed in 132 cases and 121 controls,
SL genotype in 83 cases and 96 controls, while SS genotype
was found in 43 cases and 42 controls (Table 2). When
combining genotypes, no signiﬁcant diﬀerence was found in
the frequency of the iNOS LL genotype versus the frequency
of combined SL and SS genotypes (Table 2).
No association has been observed between asbestosis
and smoking (ever/never) (OR = 0.98, 95% CI = 0.69–
1.39). Cumulative asbestos exposure was logarithmically
transformed, leading to an OR of asbestosis of 3.21 (95%
CI = 2.43–4.23).Journal of Biomedicine and Biotechnology 3
Table 2: Frequencies of iNOS genotypes in cases and controls.
Cases (n = 258) Controls (n = 259)
iNOS genotype N % n %
LL 132 51.2 121 46.7
SL 83 32.1 96 37.1
SS 43 16.7 42 16.2
SL + SS 126 48.8 138 53.3
Table 3: Risk of asbestosis for the iNOS LL genotype versus the
combined SL and SS genotypes after adjustment by gender, age,
smoking, and cumulative asbestos exposure.
OR 95% CI
Unadjusted 1.20 0.85–1.69
Adjusted by
Gender 1.20 0.85–1.70
Age 1.19 0.84–1.69
Smoking(ever/never) 1.17 0.83–1.66
Cumulative exposure 1.19 0.82–1.73
Determining the associations between iNOS genotypes
andasbestosis, theOR ofasbestosis was 1.07(95%CI =0.65–
1.74) for the LL genotype versus SS genotype, 1.26 (95% CI
= 0.86–1.85) for the LL genotype compared to SL genotype,
0.84 (95% CI = 0.50–1.42) for the SL genotype versus SS
genotype,and1.20(95%CI=0.85–1.69)fortheLLgenotype
compared to the combined SL and SS genotypes. The risk
of asbestosis for the iNOS LL genotype versus the combined
SL and SS genotypes remained practically unchanged after
adjustmentbygender,age,smoking,andcumulativeasbestos
exposure (Table 3).
4.Discussion
It has been suggested that iNOS-derived NO may play
an important role in the development of asbestos-related
diseases [5, 6, 13–15]. In a nested case-control study the
authors investigated the inﬂuence of the iNOS (CCTTT)n
polymorphismontherisk ofdevelopingasbestosis. Aslightly
(20%) higher risk of asbestosis for the iNOS LL genotype
compared to the combined SL and SS genotypes and almost
30% for the LL versus SL genotype has been detected.
This ﬁnding, although borderline signiﬁcant, could be in
agreementwiththeobservationsofsome otherstudieswhich
demonstrated an association between a disease and longer
forms of (CCTTT)n repeat in the iNOS promoter region
[18, 20, 21]. These results could be explained by a higher
promoter activity of the iNOS gene which has been shown
to increase with the (CCTTT)n repeat number in an in
vitro study [19] and consequently increased production of
NO. Since NO is a free radical and its production has
been associated with pulmonary damage, inﬂammation, and
disease progression caused by asbestos [5, 6], our ﬁnding
could be considered as biologically plausible.
All the cases and controls who participated in this
study were recruited in a small geographical area with an
ethnically homogenous population [29]. Therefore, no bias
was introduced by genetic heterogeneity.
AlthoughtheBoard ofexpertsusedtheHRCTasawidely
recommendedmethodforthediagnosisofasbestosis [25,26]
in all subjects, there is still a slight possibility that some
subjects might have been recruited as controls when they
had already developed asbestosis, which could be diagnosed
only by the histopathological examination. In that case,
we would have more subjects with asbestosis. Considering
that our study included cases who had iNOS LL genotype
more frequently than the controls, the association between
asbestosis and iNOS LL genotype might have been slightly
stronger in that case.
In conclusion, to our knowledge, this is the ﬁrst study
investigating the association between asbestosis and iNOS
genetic polymorphism. Considering that the results of the
current study are borderline signiﬁcant, further studies
including a larger number of subjects are needed to clarify
this association.
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